Implementation of Precision Medicine in High-risk Prostate Cancer

Summary

This project's objective is to initiate a prospective non-interventional clinical study to perform full molecular characterization and subtyping of the primary tumor prostate cancer patients. It will identify, compare, and select biomarkers for treatment response in high-risk/metastatic prostate cancer.

Eligibility

Inclusion Criteria:

* Men investigated for suspected prostate cancer
* Signed consent form

Exclusion Criteria:

* Difficulties understanding information about the study due to linguistic, cognitive or other reason

Conditions2

Interventions1

Related trials

• ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) — UNICANCER
• Metastasis-directed Therapy for Oligorecurrent Prostate Cancer — Universitaire Ziekenhuizen KU Leuven
• Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging — UNICANCER
• PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer — University of Miami
• PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. — M.D. Anderson Cancer Center
• Pembro With Radiation With or Without Olaparib — Zin W Myint

Browse More Trials